Available Technologies: Health Sciences

Australian Bush Bioactives

Australian Bush BioactivesThe significance of this project relates to the potential to develop a new topical, non-steroidal antiinflammatory treatment for dermatitis and psoriasis. Compounds in development are unrelated to those in current clinical use, possibly with a novel mechanism of action and improved safety profile.

Benefits

  • Novel bioactives display nonsteroidal anti-inflammatory activity
  • Equivalent efficacy to corticosteroids
  • Novel mechanism of action
  • Safe, clear and odourless extract
  • Socially, ethically and sustainable entrepreneurship project supporting Aboriginal homeland communities

Background

The significance of this project relates to the potential to develop a new topical, non-steroidal antiinflammatory treatment for dermatitis and psoriasis. Compounds in development are unrelated to those in current clinical use, possibly with a novel mechanism of action and improved safety profile. Topical steroids are widely used in the management of inflammatory skin conditions such as dermatitis and psoriasis. While topical steroids therapies are generally effective and well tolerated when used at low strengths and on a short-term basis, the need to use more potent steroids on a more long term-basis in more severe disease can have undesirable side effects. The limitations of these therapies, particularly in terms of their sideeffect profiles, has driven the ongoing search for new drug entities potentially with novel mechanisms of action and improved safety profiles.

Technology

Novel compounds of the clerodane furanoditerpenoid type have been extracted and isolated from the native Australian plant, Dodonea polyandra. Using a well-established animal model of skin inflammation we have demonstrated compounds have antiinflammatory activity.

This activity is comparable to that seen with commonly used steroidal anti-inflammatory agents (including hydrocortisone and betamethasone) in the same model.

In addition, initial work has indicated the compounds have a different mechanism of action from other commonly used non-steroidal antiinflammatory agents.

Potential markets

Compounds and/or botanical extracts can be used in the following three markets:

  1. Therapeutic anti-inflammatory market
  2. Complementary and Alternative Therapies
  3. Natural personal care

IP Status

The technology has received a clear International Preliminary Report on Patentability from IP Australia recognising compound, methods and composition claims as both novel and inventive. The technology has been protected in Australia, US, Japan and Europe.

Partnering opportunities

We are seeking co-development partners and technology licensees for the development of therapeutic antiinflammatory pharmcaeuticals, complementary and alternative therapies and personal care products. Our current focus is the development of topical formulations for treatment of dermatitis and psoriasis however compound could also be made available for testing on other animal models to interested parties.

Inventor

  • Dr Susan Semple, University of South Australia
  • Dr Bradley.Simpson, University of South Australia
  • Dr Cobus Gerber, University of South Australia
  • Prof Ross McKinnon, Flinders University
  • Mr David Claudie and Mr George Moreton, Chuulangun Aboriginal Corporation
  • Dr Jiping Wang, Monash University

Commercial lead